1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Roivant Sciences Ltd.

Roivant Sciences Ltd.

ROIVW
Roivant Sciences Ltd.US flagNASDAQ Global Market
2.75
USD
+0.12
- -
1.97BMarket Cap
No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChatGPT
CEO
Matthew Gline
Full Time Employees
620
Sector
Healthcare
Industry
Biotechnology
Address
11-12 St. James’s Square London United Kingdom SW1Y 4LB
IPO Date
Sep 27, 2021
CIK
0001635088
Website
roivant.com
Similar Companies
Paratek Pharmaceuticals, Inc. (PRTK)
Oxford Cannabinoid Technologies Holdings Plc (OCTP.L)
Zevra Therapeutics, Inc. (ZVRA)
Omnimmune Holdings, Inc. (OMMH)
Chemomab Therapeutics Ltd. (CMMB)
SanBio Company Limited (4592.T)
Business
Roivant Sciences Ltd. is a biopharmaceutical firm and healthcare technology innovator dedicated to discovering and advancing new therapies. The company operates through a distinctive "Vant" model, establishing specialized subsidiaries that concentrate on developing product candidates across a diverse range of therapeutic areas. These include autoimmune disorders, dermatologic conditions like psoriasis and atopic dermatitis, neurological diseases such as Alzheimer's, various oncologic indications, and rare illnesses. Utilizing this approach, Roivant aims to accelerate the development of medicines for conditions with significant unmet patient needs. The company was established in 2014 and is headquartered in New York City, U.S.